Mycosis Fungoides and Sezary Syndrome — Trials

Mycosis Fungoides and Sezary Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 32
Recruiting: 15
Ph III recruiting: 0
Growth YoY: —
Industry share: 13%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 44.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 1–14 of 14 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05944562	Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome	active not recruiting	Phase 1	24	Washington University School of MedicineOTHER	1	Sep 16, 2026	clinicaltrials
NCT07055477	A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)	recruiting	Phase 1	60	National Cancer Institute (NCI)NIH	1